CervoMed Inc. (NASDAQ:CRVO)
| Market Cap | 26.76M-74.6% |
| Revenue (ttm) | 0-100.0% |
| Net Income | -28.52M-11.5% |
| EPS | -2.76+3.8% |
| Shares Out | 15.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,749,479 |
| Open | 1.40 |
| Previous Close | 1.37 |
| Day's Range | 1.38 - 2.09 |
| 52-Week Range | 1.27 - 10.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 7.00(+295.48%) |
| Earnings Date | Mar 12, 2027 |
About CRVO
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating CRVO in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 12, 2027Earnings report
$CRVO stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CRVO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CRVO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CRVO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CRVO Revenue by Segment
| Personnel costs, excluding stock-based compensation | $1.13M | 43.40% |
| Professional fees | $742.67K | 28.47% |
| Stock-based compensation | $307.44K | 11.79% |
| Insurance, taxes and similar fees | $217.03K | 8.32% |
| Other income | $209.52K | 8.03% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CRVO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CRVO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CRVO
| VTIVanguard Morningstar Total Stock Market ETF | $743.02K |
| VXFVanguard Extended Market ETF | $196.10K |
| IWCiShares Micro-Cap ETF | $40.16K |
| AVSCAvantis U.S. Small Cap Equity ETF | $4.49K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CRVO’s recent data — informational, not investment advice
What’s Behind the Score
News check: CRVO showed Q3 results and publication of peer-reviewed research supporting lead candidate for dementia treatment, signaling clinical progress and validation.